Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
| Autor: | Curigliano, G., Dunton, K., Rosenlund, M., Janek, M., Cathcart, J., Liu, Y., Fasching, P.A., Iwata, H. |
|---|---|
| Zdroj: | In Annals of Oncology July 2023 34(7):569-577 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|